X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Packaging & Logistic

SkyCell launches next gen 1500X pharma container

Content Team by Content Team
8th April 2022
in Packaging & Logistic, Press Statements
SkyCell launches next gen 1500X pharma container

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

SkyCell updates its container lineup with the 1500X Hybrid container with 270 hours independent runtime for temperature-sensitive pharma product transportation

New container raises the bar for protecting pharma shipments at +2°C to +8°C or +15°C to +25°C and comes fully equipped with SkyCell’s proprietary SECURE SaaS platform to ensure protection for an unbroken cold chain.

SkyCell, the innovator and leading manufacturer of temperature-controlled hybrid containers for the pharmaceutical industry, has launched the new 1500X container, the next generation in its hybrid container portfolio for high value pharmaceutical product transportation.

The 1500X enables pharma shipments for products that need to be kept at +2°C to +8°C or +15°C to +25°C and has a tested market-leading independent runtime of 270 hours at 20°C. The extended runtime ensures that the transportation of temperature-sensitive goods remains unaffected even in the event of unforeseen circumstances such as flight delays, re-routing, and delays at customs.

All round optimization

The 1500X builds on years of design and manufacturing innovation that has led SkyCell’s containers to have a verified temperature excursion rate of less than 0.1 percent and a product loss rate of 0.0 percent. Manufactured with a die-cast frame using the same technique in the construction of airplane parts, the 1500X is 120kg lighter than its predecessor but still maintains a payload capacity of up to 1,000kg. The new internal height of 1.3 meters – creating 7.8 per cent more internal volume – allows customers to transport more in each individual container and reduces costs and CO2 emissions even further. The 1500X continues to feature SkyCell’s patented double-door system to prevent humidity changes and provide added security during transit.

In further enhancements to the safety and protection of goods within the 1500X, the container’s feet have been redesigned to improve shock and vibration protection. The die-cast aluminum feet absorb impact and dampen the vibrations from aircraft and trucks that are – along with excursions outside optimal temperature range – a leading cause of in-transit product spoilage.

The 1500X is also the most space-efficient container in SkyCell’s product portfolio. Four 1500X containers can be loaded onto one standard PMC pallet, while only a pallet jack is required to load the 1500X into a standard truck that can hold up to 18 containers.

Loading the container itself is an almost effortless process: open, load goods, close, and ship.

Previous Post

1 billion vaccine doses: Emirates SkyCargo surpasses a historic landmark for COVID-19 vaccine transportation

Next Post

Turkish Cargo carried 335 Million Doses of Covid-19 Vaccine to 61 Countries During 2021

Related Posts

Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
Future Trends Shaping
Packaging & Logistic

Future Trends Shaping Pharma Supply Chain and Logistics

30th July 2025
GSK and Hengrui Pharma
Drug Development

GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology

29th July 2025
Aptar Pharma Bolsters Clinical Trial.
Clinical Trials

Aptar Pharma Bolsters Clinical Trial Capabilities with Strategic Materials Manufacturing Acquisition

24th July 2025
Next Post
Turkish Cargo carried 335 Million Doses of Covid-19 Vaccine to 61 Countries During 2021

Turkish Cargo carried 335 Million Doses of Covid-19 Vaccine to 61 Countries During 2021

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In